Skip to main content
SpringerLink
Log in

Transforming growth factor-β and multidrug resistance in chronic lymphocytic leukemia

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Patients with chronic lymphocytic leukemia (CLL) frequently respond to initial treatment, but then become resistant to chemotherapy. Studies have shown one important cause of chemotherapeutic resistance to be multidrug resistance (MDR). To investigate the potential role of MDR and transforming growth factor-β (TFG-β), a potent growth inhibitor of B lymphocytes, in the development of chemotherapeutic resistance in CLL, we evaluated 22 CLL patients for loss or mutation of TGF-β receptors (TβR), plasma TGF-β1 levels, and expression of MDR1 mRNA. Receptor crosslinking and immunoprecipitation experiments did not demonstrate loss of TβRs in any patients studied. No relationship between plasma TGF-β1 levels and expression of MDR1 mRNA was seen. Correlation of plasma TGF-β1 levels to disease stage revealed a consistent decline in plasma TGF-β1 levels with advancing disease stage (P=0.031).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges.J Cell Biol 1992;119: 1017.

    Article  CAS  PubMed  Google Scholar 

  2. Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation.Cancer Res 1995;55: 1452.

    CAS  PubMed  Google Scholar 

  3. Bursch Wet al. Transforming growth factor-β1 as a signal for induction of cell death by apoptosis.Br J Cancer 1993;67: 531.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-β.Blood 1997;89: 941.

    Article  CAS  PubMed  Google Scholar 

  5. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis.Crit Rev Oncol 1993;4: 493.

    CAS  Google Scholar 

  6. Glick AB, Weinberg WC, Wu I-H, Quan W, Yuspa SH. Transforming growth factor β1 suppresses genomic instability independent of a G arrest,p53 and Rb.Cancer Res 1996;56: 3645.

    CAS  PubMed  Google Scholar 

  7. Hopkin K. The TGF-β signaling pathway: a new model with no middle.J NIH Res 1994;6: 40.

    Google Scholar 

  8. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-β pathway in human cancers.Cytokine Growth Factor Rev 1996;7: 93.

    Article  CAS  PubMed  Google Scholar 

  9. Marx J. DNA repair defect tied to mutated TGF-β receptor gene.Science 1995;268: 1276.

    Article  CAS  PubMed  Google Scholar 

  10. Massagué Jet al. Transforming growth factor-β.Cancer Surv 1992;12: 81.

    PubMed  Google Scholar 

  11. McCartney-Francis NL, Wahl SM. Transforming growth factor β: a matter of life and death.J Leukoc Biol 1994;55: 401.

    Article  CAS  PubMed  Google Scholar 

  12. Serra R, Moses HL. Tumor suppressor genes in the TGF-β signaling pathway?Nat Med 1996;2: 390.

    Article  CAS  PubMed  Google Scholar 

  13. Teicher BAet al. Reversal ofin vivo drug resistance by the transforming growth factor-β inhibitor decorin.Int J Cancer 1997;71: 49.

    Article  CAS  PubMed  Google Scholar 

  14. Teicher BA, Holden SA, Ara G, Chen G. Transforming growth factor-β inin vivo resistance.Cancer Chemother Pharmacol 1996;37: 601.

    Article  CAS  PubMed  Google Scholar 

  15. Urashima Met al. Transforming growth factor-β1: differential effects on multiple myeloma versus normal B cells.Blood 1996;87: 1928.

    Article  CAS  PubMed  Google Scholar 

  16. Utsunomiya Y, Hasegawa H, Yanagisawa K, Fujita S. Enhancement ofmdr1 gene expression by transforming growth factor-β1 in the new adriamycin-resistant human leukemia cell line ME-F2/ADM.Leukemia 1997;11: 894.

    Article  CAS  PubMed  Google Scholar 

  17. Kehrl JHet al. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.J Immunol 1986;137: 3855.

    Article  CAS  PubMed  Google Scholar 

  18. Kehrl JHet al. Further studies of the role of transforming growth factor-beta in human B cell function.J Immunol 1989;143: 1868.

    Article  CAS  PubMed  Google Scholar 

  19. Israels LGet al. Role of transforming growth factor-β in chronic lymphocytic leukemia.Leukemia Res 1993;17: 81.

    Article  CAS  Google Scholar 

  20. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor β as endogenous growth inhibitor of chronic lymphocytic leukemia B cells.J Exp Med 1994;179: 999.

    Article  CAS  PubMed  Google Scholar 

  21. Markowitz Set al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.Science 1995;268: 1336.

    Article  CAS  PubMed  Google Scholar 

  22. Kakeji Y, Teicher BA. Induction of transforming growth factor-β (TGF-β) by cytotoxic anticancer therapies and its potential role in the development of therapeutic resistance.Proc Am Assoc Cancer Res 1996;37: 35.

    Google Scholar 

  23. DeCoteau JFet al. Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia.Proc Natl Acad Sci USA 1997;94: 5877.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Yasumi Ket al. Transforming growth factor β type II receptor (TGFβRII) mutation in gastric lymphoma without mutator phenotype.Pathol Int 1998;48: 134–137.

    Article  CAS  PubMed  Google Scholar 

  25. Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ. Consistent loss of functional transforming growth factor β receptor expression in murine plasmacytomas.Proc Natl Acad Sci USA 1998;95: 189–194.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. De Met al. Functional characterization of transforming growth factor β type II receptor mutants in human cancer.Cancer Res 1998;58: 1986–1992.

    CAS  PubMed  Google Scholar 

  27. Pasche Bet al. Type I transforming growth factor β receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract.Cancer Res 1998;58: 2727–2732.

    CAS  PubMed  Google Scholar 

  28. Cumber PMet al. Expression of the multiple drug resistance gene (MDR-1) and epitope masking in chronic lymphatic leukaemia.Br J Haematol 1990;76: 226.

    Article  CAS  PubMed  Google Scholar 

  29. El Rouby Set al. P53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent ofMDR1/MDR3 gene expression.Blood 1993;82: 3452.

    Article  PubMed  Google Scholar 

  30. Friedenberg WRet al. Multi-drug resistance in chronic lymphocytic leukemia.Leuk Lymph (in press).

  31. Herweijer H, Sonneveld P, Baas F, Nooter K. Expression ofmdr1 andmdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.J Natl Cancer Inst 1990;82: 1133.

    Article  CAS  PubMed  Google Scholar 

  32. Holmes JAet al. Is theMDR1 gene relevant in chronic lymphocytic leukemia?Leukemia 1990;4: 216.

    CAS  PubMed  Google Scholar 

  33. Ludescher Cet al. Activity of p-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.J Natl Cancer Inst 1993;85: 1751.

    Article  CAS  PubMed  Google Scholar 

  34. Michieli Met al. The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia.Br J Haematol 1991;77: 460.

    Article  CAS  PubMed  Google Scholar 

  35. Shustik C, Groulx N, Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL).Br J Haematol 1991;79: 50.

    Article  CAS  PubMed  Google Scholar 

  36. Sonneveld Pet al. High expression of the MDR3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia.Blood 1992;79: 1496.

    Article  CAS  PubMed  Google Scholar 

  37. Sparrow RL, Hall FJ, Siregar H, Van Der Weyden MB. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation within vitro drug resistance.Leuk Res 1993;17: 941.

    Article  CAS  PubMed  Google Scholar 

  38. Rochlitz CFet al. PCR-determined expression of theMDR1 gene in chronic lymphocytic leukemia.Ann Hematol 1992;65: 241–246.

    Article  CAS  PubMed  Google Scholar 

  39. Wallner Jet al.MDR1 gene expression in chronic lymphocytic leukemia.Leuk Lymph 1994;13: 333–338.

    Article  CAS  Google Scholar 

  40. Beck WTet al. Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.Cancer Res 1996;56: 3010–3020.

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. William R Friedenberg

    Present address: Department of Hematology/Oncology, Guthrie Clinic, 18840, Sayre, PA, USA

Authors and Affiliations

  1. Department of Hematology/Oncology, Marshfield Clinic, Marshfield, Wisconsin, USA

    William R Friedenberg

  2. Marshfield Medical Research Foundation, 1000 North Oak Avenue, 54449, Marshfield, WI, USA

    Sherry A Salzman, Sonja M Phan & James K Burmester

Authors
  1. William R Friedenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sherry A Salzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sonja M Phan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James K Burmester
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James K Burmester.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friedenberg, W.R., Salzman, S.A., Phan, S.M. et al. Transforming growth factor-β and multidrug resistance in chronic lymphocytic leukemia. Med Oncol 16, 110–118 (1999). https://doi.org/10.1007/BF02785844

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02785844

Keywords

Search

Navigation